#Melanoma

The NIH has said it will pour nearly $200 million into developing cancer vaccines starting in December.

Personalized Moderna and Merck vaccine, called intismeran, was made with same Nobel Prize-winning mRNA technology behind COVID-19 vaccines

It's been 20 years since Australian researchers created the world's first vaccine developed specifically to prevent cancer.

In a world-first, adding a vaccine tailored to a patient’s tumour to standard immunotherapy improved two-year recurrence-free outcomes; Tata Memorial Hospital oncologist says longer follow-up and affordability remain key questions

The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.

Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful result for melanoma patients who underwent surgery.

Long-awaited results from phase III trial show huge benefits for treatment-resistant melanoma.

The scientists involved say the results could mark a turning point in cancer treatment, bringing personalised medicine a step closer.

The study included more than 1,100 people with high-risk melanoma that had been surgically removed.

Trial results represent ‘foundational shift’ in approach to cancer, allowing scientists to harness immune system in more personalised way

Beyond melanoma, scientists are studying cancer vaccines for glioblastoma, pancreatic cancer and more.

Merck and Moderna released detailed results on an experimental vaccine to treat the skin cancer.

Melanoma vaccine treatment cut risk of recurrence or death by 58% but failed to exceed Wall Street’s lofty expectations

The melanoma doctor's brain cancer treatment experiment has sparked hope for a breakthrough.

From Independent RSS Feed: Skin cancer warning as one in nine Britons admit to deliberately burning themselves to tan

Despite their popularity, scientists still do not know whether tattoos have any impact on health

A key protein, HOXD13, helps melanoma tumors grow and evade the immune system by boosting blood supply and blocking cancer-fighting T cells. Disabling it shrinks tumors and reopens the door for the immune system—offering a new path for treatment.

A massive Swedish study shows that AI can spot people at higher risk of melanoma using routine health data. Advanced models significantly outperformed basic methods, identifying high-risk groups with striking accuracy.…